The IARC TP53 database: New online mutation analysis and recommendations to users

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463

p53 and Human Cancer: The First Ten Thousand Mutations

Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999

Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome

Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M. L., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 899

Database of p53 gene somatic mutations in human tumors and cell lines.

Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858

Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73

Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241

p53 gene mutation: software and database

Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185

p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.

Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180

p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer

Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164

p53 and the Li-Fraumeni syndrome

Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153

p53 gene mutation: software and database

Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149

Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells

Nicolaou, K. A., Liapis, V., Evdokiou, A., Constantinou, C., Magiatis, P., Skaltsounis, A., Koumas, L., Costeas, P., & Constantinou, A. I. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.053 · Cited by 33

G-actin guides p53 nuclear transport: potential contribution of monomeric actin in altered localization of mutant p53

Saha, T., Guha, D., Manna, A., Panda, A. K., Bhat, J., Chatterjee, S., & Sa, G. (2016) · Scientific Reports · doi:10.1038/srep32626 · Cited by 32

Gene expression profiling analysis reveals arsenic-induced cell cycle arrest and apoptosis in p53-proficient and p53-deficient cells through differential gene pathways

Yu, X., Robinson, J. F., Gribble, E. J., Hong, S. W., Sidhu, J. S., & Faustman, E. M. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.09.016 · Cited by 34

Inhibitors of MDM2 and MDMX: A Structural Perspective

Riedinger, C., & McDonnell, J. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.75 · Cited by 32

Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene

Kong, Y., Lu, Z., Wang, J., Zhou, R., Guo, J., Liu, J., Sun, H., He, W., Song, W., Yang, J., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4935 · Cited by 33

The mutational spectrum in whole exon of p53 in oral squamous cell carcinoma and its clinical implications

Hyodo, T., Kuribayashi, N., Fukumoto, C., Komiyama, Y., Shiraishi, R., Kamimura, R., Sawatani, Y., Yaguchi, E., Hasegawa, T., Izumi, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25744-8 · Cited by 32

Prospects for p53-based cancer therapy.

Stokłosa, T., & Gołąb, J. (2005) · Acta Biochimica Polonica · doi:10.18388/abp.2005_3445 · Cited by 32

Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells

Xie, T., Zhou, G., Zhao, M., Sano, D., Jasser, S. A., Brennan, R. G., & Myers, J. N. (2013) · The Laryngoscope · doi:10.1002/lary.23846 · Cited by 31

Suicidal function of DNA methylation in age-related genome disintegration

Mazin, A. L. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.04.005 · Cited by 32

The Insulin and IGF-I Pathway in Endocrine Glands Carcinogenesis

Malaguarnera, R., Morcavallo, A., & Belfiore, A. (2012) · Journal of Oncology · doi:10.1155/2012/635614 · Cited by 33

Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting

Tan, Y. S., Mhoumadi, Y., & Verma, C. S. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz009 · Cited by 34

Arrayed identification of DNA signatures

Käller, M., Lundeberg, J., & Ahmadian, A. (2006) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.1.65 · Cited by 32

Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson

Menéndez, D., Inga, A., Jordan, J. J., & Resnick, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210277 · Cited by 32

Mechanisms of esophageal cancer development in Brazilians

Pinto, L. F. R. (2003) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2003.06.021 · Cited by 32

Machine learning for genomic profiling and drug discovery in personalised lung cancer therapeutics

Ahmad, S., Shah, S. N. A., Parveen, R., & Raza, K. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2530656 · Cited by 36

TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3

Jha, P., Jha, P., Pathak, P., Chosdol, K., Suri, V. S., Sharma, M. C., Kumar, G., Singh, M., Mahapatra, A. K., & Sarkar, C. (2010) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2010.11.002 · Cited by 31

Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN

Zhang, J., Xu, E., Ren, C., Yang, H. J., Zhang, Y., Sun, W., Kong, X., Zhang, W., Chen, M., Huang, E. C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2457 · Cited by 31

Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A

Shen, T., Shang, C., Zhou, H., Luo, Y., Barzegar, M., Odaka, Y., Wu, Y., & Huang, S. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.135 · Cited by 31

Activation of cAMP Signaling Interferes with Stress-Induced p53 Accumulation in ALL-Derived Cells by Promoting the Interaction between p53 and HDM2

Naderi, E. H., Jochemsen, A. G., Blomhoff, H. K., & Naderi, S. (2011) · Neoplasia · doi:10.1593/neo.11542 · Cited by 33

The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer

Moore, H. C., Jordan, L. B., Bray, S. E., Baker, L., Quinlan, P., Purdie, C. A., Thompson, A. M., Bourdon, J., & Fuller-Pace, F. V. (2010) · Oncogene · doi:10.1038/onc.2010.381 · Cited by 33

Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis

Khan, M. H., Khalil, A., & Rashid, H. (2015) · Genetics Research · doi:10.1017/s0016672315000075 · Cited by 31

TP53 overexpression in recurrent endometrial carcinoma

Pijnenborg, J. M. A., van de Broek, L., de Veen, G. C. D., Roemen, G. M. J. M., de Haan, J., van Engeland, M., Voncken, J. W., & Groothuis, P. G. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.056 · Cited by 31

PRIMA-1MET induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins

Rökaeus, N., Klein, G., Wiman, K. G., Székely, L., & Mattsson, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209858 · Cited by 31

Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes

Haley, V., Barnes, D., Sandovici, I., Constância, M., Graham, C. F., Pezzella, F., Bühnemann, C., Carter, E. J., & Hassan, A. B. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101105 · Cited by 30

The CDKN2A database: Integrating allelic variants with evolution, structure, function, and disease association

Murphy, J. A., Barrantes-Reynolds, R., Kocherlakota, R., Bond, J. P., & Greenblatt, M. S. (2004) · Human Mutation · doi:10.1002/humu.20083 · Cited by 31

Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo

Palacios, G. F., & Moll, U. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209641 · Cited by 31

Detection of p53 and K-ras mutations in sputum of individuals exposed to smoky coal emissions in Xuan Wei County, China

Keohavong, P. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh328 · Cited by 31

Overexpression of p53 protein in human tumors

Inoue, K., Kurabayashi, A., Shuin, T., Ohtsuki, Y., & Furihata, M. (2012) · Medical Molecular Morphology · doi:10.1007/s00795-012-0575-6 · Cited by 29

Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA

Lepre, M. G., Omar, S. I., Grasso, G., Morbiducci, U., Deriu, M. A., & Tuszyński, J. A. (2017) · Molecules · doi:10.3390/molecules22081358 · Cited by 31

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years

Petridis, C., Arora, I., Shah, V., Megalios, A., Moss, C. L., Mera, A., Clifford, A., Gillett, C., Pinder, S. E., Tomlinson, I. P. M., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1143-y · Cited by 30

p53 in Proximal Tubules Mediates Chronic Kidney Problems after Cisplatin Treatment

Fu, S., Hu, X., Ma, Z., Wei, Q., Xiang, X., Li, S., Wen, L., Liang, Y., & Dong, Z. (2022) · Cells · doi:10.3390/cells11040712 · Cited by 30

p53: a molecular marker for the detection of cancer

Boyd, M. T., & Vlatković, N. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2.9.1013 · Cited by 30

Inhibition of Retinoblastoma In Vitro and In Vivo with Conditionally Replicating Oncolytic Adenovirus H101

Song, X., Zhou, Y., Jia, R., Xu, X., Wang, H., Hu, J., Ge, S., & Fan, X. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3516 · Cited by 30

p53 Binds to Estrogen Receptor 1 Promoter in Human Breast Cancer Cells

Rasti, M., Arabsolghar, R., Khatooni, Z., & Mostafavi‐Pour, Z. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9423-6 · Cited by 30

Applications of the human p53 knock‐in ( Hupki ) mouse model for human carcinogen testing

Nia, A. B., & Pfeifer, G. P. (2010) · The FASEB Journal · doi:10.1096/fj.10-157263 · Cited by 31

p53 and its mutants on the slippery road from stemness to carcinogenesis

Molchadsky, A., & Rotter, V. (2017) · Carcinogenesis · doi:10.1093/carcin/bgw092 · Cited by 30

Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma

Feuerborn, A., Möritz, C., von Bonin, F., Dobbelstein, M., Trümper, L. H. P., Stürzenhofecker, B., & Kube, D. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600667721 · Cited by 30

In silico p53 mutation hotspots in lung cancer

Lewis, P. D. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh068 · Cited by 30

Does control of mutant p53 by Mdm2 complicate cancer therapy?: Figure 1.Preprint

Prives, C. L., & White, E. (2008) · Genes & Development · doi:10.1101/gad.1680508 · Cited by 30

Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer

Oshima, K., Naoi, Y., Kishi, K., Nakamura, Y., Iwamoto, T., Shimazu, K., Nakayama, T., Kim, S. J., Baba, Y., Tamaki, Y., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.027 · Cited by 29

Genotype–phenotype associations among panel-based TP53+ subjects

Rana, H. Q., Clifford, J., Hoang, L., LaDuca, H., Black, M. H., Li, S., McGoldrick, K., Speare, V., Dolinsky, J. S., Gau, C., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0541-y · Cited by 31

TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer

Akula, S. M., Ruvolo, P. P., & McCubrey, J. A. (2020) · Aging · doi:10.18632/aging.102776 · Cited by 29

Germline mutations of TP53 gene in breast cancer

Damineni, S., Rao, V. R., Kumar, S., Ravuri, R. R., Kagitha, S., Dunna, N. R., Digumarthi, R., & Satti, V. (2014) · Tumor Biology · doi:10.1007/s13277-014-2176-6 · Cited by 29

Lack of p53 induction in fish cells by model chemotherapeutics

Embry, M. R., Billiard, S. M., & Giulio, R. T. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209238 · Cited by 29

CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers

On Behalf of the Group for Assessment of Hereditary Cancer of Valencia Community, Suela, S. P., Cardeñosa, E. E., Barragán-González, E., Jiménez, I. D. J., Chirivella, I., Huerta, Á. S., Guillén‐Ponce, C., de Dueñas, E. M., Salcedo, J. M., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0316-2 · Cited by 29

Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53

Dixit, U., Liu, Z., Pandey, A. K., Kothari, R. K., & Pandey, V. N. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-925 · Cited by 28

Geographical Variations in TP53 Mutational Spectrum in Ovarian Carcinomas

Dansonka‐Mieszkowska, A., Ludwig‐Słomczyńska, A. H., Kraszewska, E., & Kupryjańczyk, J. (2006) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2006.00257.x · Cited by 29

The Flavonoid Quercetin Transiently Inhibits the Activity of Taxol and Nocodazole Through Interference With the Cell Cycle

Samuel, T., Fadlalla, K., Turner, T., & Yehualaeshet, T. (2010) · Nutrition and Cancer · doi:10.1080/01635581.2010.492087 · Cited by 29

Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: Differential diagnosis between refractory anemia and aplastic anemia

Iwasaki, T., Murakami, M., Sugisaki, C., Sobue, S., Ohashi, H., Asano, H., Suzuki, M., Nakamura, S., Ito, M., & Murate, T. (2008) · Pathology International · doi:10.1111/j.1440-1827.2008.02236.x · Cited by 29

A Kepler Workflow Tool for Reproducible AMBER GPU Molecular Dynamics

Purawat, S., Ieong, P. U., Malmstrom, R. D., Chan, G. J., Yeung, A. K., Walker, R. C., Altıntaş, İ., & Amaro, R. E. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.04.055 · Cited by 30

p53 and chemosensitivity in bladder cancer

Nishiyama, H., Watanabe, J., & Ogawa, O. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0815-x · Cited by 28

Tetramerization‐defects of p53 result in aberrant ubiquitylation and transcriptional activity

Lang, V., Pallara, C., Zabala‐Letona, A., Lobato-Gil, S., Lopitz‐Otsoa, F., Farrás, R., Hjerpe, R., Torres-Ramos, M., Zabaleta, L., Blattner, C., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.04.002 · Cited by 29

Functional analysis of p53 tumor suppressor in yeast

Šmardová, J., Šmarda, J., & Koptíková, J. (2005) · Differentiation · doi:10.1111/j.1432-0436.2005.00028.x · Cited by 29

Orthotopic Implantation of Human Hepatocellular Carcinoma in Mice

Armengol, C., Tarafa, G., Boix, L., Solé, M., Queralt, R., Costa, D., Bachs, O., Bruix, J., & Capellá, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-1028 · Cited by 28

p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo

Pérez‐Losada, J., Wu, D., Delrosario, R., Balmain, A., & Mao, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208799 · Cited by 29

ProPhylER: A curated online resource for protein function and structure based on evolutionary constraint analysesPreprint

Binkley, J., Karra, K., Kirby, A. W., Hosobuchi, M., Stone, E. A., & Sidow, A. (2009) · Genome Research · doi:10.1101/gr.097121.109 · Cited by 29

R248Q mutation—Beyond p53‐ DNA binding

Ng, J. W. K., Lama, D., Lukman, S., Lane, D. P., Verma, C. S., & Sim, A. Y. L. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24940 · Cited by 28

The path to metastatic mouse models of colorectal cancer

Romano, G., Chagani, S., & Kwong, L. N. (2018) · Oncogene · doi:10.1038/s41388-018-0155-x · Cited by 32

Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity

Cui, L., Zhou, F., Chen, C., & Wang, C. C. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0479-3 · Cited by 28

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments

Granowicz, E. M., & Jonas, B. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s265637 · Cited by 31

Surface cholesterol-enriched domains specifically promote invasion of breast cancer cell lines by controlling invadopodia and extracellular matrix degradation

Maja, M., Mohammed, D., Dumitru, A. C., Verstraeten, S. L., Lingurski, M., Mingeot‐Leclercq, M., Alsteens, D., & Tyteca, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04426-8 · Cited by 29

Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells

Romani, A. A., Desenzani, S., Morganti, M. M., Monica, S. L., Borghetti, A. F., & Soliani, P. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.004 · Cited by 28

PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-Type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A

Cui, B., Yang, Q., Guan, H., Shi, B., Hou, P., & Ji, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3147 · Cited by 28

The screening of the second‐site suppressor mutations of the common p53 mutants

Otsuka, K., Kato, S., Kakudo, Y., Mashiko, S., Shibata, H., & Ishioka, C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22724 · Cited by 28

Exploring functional variant discovery in non-coding regions with SInBaD

Lehmann, K.-V., & Chen, T. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks800 · Cited by 27

Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy

Kaur, T., Slavcev, R. A., & Wettig, S. D. (2009) · Current Gene Therapy · doi:10.2174/156652309790031148 · Cited by 28

Hyperthermia exposure induces apoptosis and inhibits proliferation in HCT116 cells by upregulating miR‑34a and causing transcriptional activation of p53

Luo, Z., Zheng, K., Fan, Q., Jiang, X., & Xiong, D. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5257 · Cited by 28

O 6 -methylguanine–induced transcriptional mutagenesis reduces p53 tumor-suppressor function

Ezerskyte, M., Paredes, J. A., Malvezzi, S., Burns, J. A., Margison, G. P., Olsson, M., Scicchitano, D. A., & Dreij, K. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721764115 · Cited by 30

Mutation hotspots in the p53 gene in tumors of different origin: correlation with evolutionary conservation and signs of positive selection

Glazko, G. V., Koonin, E. V., & Rogozin, I. B. (2004) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2004.05.004 · Cited by 28

Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-α on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells

Charlot, J., Nicolier, M., Prétet, J., & Mougin, C. (2006) · APOPTOSIS · doi:10.1007/s10495-006-5876-6 · Cited by 32

Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France)

Breton, J. (2003) · Mutagenesis · doi:10.1093/mutage/18.3.299 · Cited by 28

Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer

Scalise, C. B., Soloff, A. C., Ethier, S. P., & Yeh, E. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.008 · Cited by 27

Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival: Analyses of gene mutations, protein expression, and loss of heterozygosity in Japanese patients

Egashira, A., Morita, M., Yoshida, R., Saeki, H., Oki, E., Sadanaga, N., Kakeji, Y., Tsujitani, S., & Maehara, Y. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21920 · Cited by 28

Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers

Lamolle, G., Marı́n, M., & Álvarez-Valín, F. (2006) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.03.004 · Cited by 27

MicroRNA‐34a is an important component of PRIMA‐1‐induced apoptotic network in human lung cancer cells

Duan, W., Gao, L., Wu, X., Wang, L., Nana-Sinkam, S. P., Otterson, G. A., & Villalona-Calero, M. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.25049 · Cited by 27

A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens

Keimling, M., Kaur, J., Bagadi, S. A. R., Kreienberg, R., Wiesmüller, L., & Ralhan, R. (2008) · International Journal of Cancer · doi:10.1002/ijc.23551 · Cited by 27

IKK-β mediates chemoresistance by sequestering FOXO3; A critical factor for cell survival and death

Tezil, T., Bodur, Ç., Kütük, Ö., & Başağa, H. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.012 · Cited by 27

Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer

Vojtesek (2009) · Oncology Reports · doi:10.3892/or_00000556 · Cited by 27

CUL7 promotes cancer cell survival through promoting Caspase‐8 ubiquitination

Kong, Y., Wang, Z., Huang, M., Zhou, Z., Li, Y., Miao, H., Wan, X., Huang, J., Mao, X., & Chen, C. (2019) · International Journal of Cancer · doi:10.1002/ijc.32239 · Cited by 27

Risk of p53 gene mutation in esophageal squamous cell carcinoma and habit of betel quid chewing in Taiwanese

Goan, Y., Chang, H., Hsu, H., Chou, Y., & Cheng, J. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00115.x · Cited by 27

Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations

Martínez, R., Roggendorf, W., Baretton, G. B., Klein, R., Toedt, G., Lichter, P., Schackert, G., & Joos, S. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.01.006 · Cited by 27

Methylation and repeats in silent and nonsense mutations of p53

Kouidou, S., Malousi, A., & Maglaveras, N. (2006) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.03.002 · Cited by 27

Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma

Chen, C., Dickman, K. G., Huang, C., Shun, C., Tai, H., Huang, K., Wang, S., Lee, Y., Grollman, A. P., & Pu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9904 · Cited by 27

Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer

Liu, Y., Xu, F., Wang, Y., Wu, Q., Wang, B., Yao, Y., Zhang, Y., Han‐Zhang, H., Ye, J., Zhang, L., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10625 · Cited by 26

Overlapping Group Logistic Regression with Applications to Genetic Pathway Selection

Zeng, Y., & Breheny, P. J. (2016) · Iowa Research Online (University of Iowa) · Cited by 26

The Changes in the p53 Protein across the Animal Kingdom Point to Its Involvement in Longevity

Bartas, M., Brázda, V., Volná, A., Červeň, J., Pečínka, P., & Zawacka‐Pankau, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168512 · Cited by 29

New approaches for biomonitoring exposure to the human carcinogen aristolochic acid

Yun, B. H., Sidorenko, V. S., Rosenquist, T. A., Dickman, K. G., Grollman, A. P., & Turesky, R. J. (2015) · Toxicology Research · doi:10.1039/c5tx00052a · Cited by 26

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma

Ognjanovic, S., Martel‐Planche, G., Manivel, C. J., Olivier, M., Langer, E. K., & Hainaut, P. L. (2012) · Sarcoma · doi:10.1155/2012/492086 · Cited by 26

Sodium Arsenite ± Hyperthermia Sensitizes p53-Expressing Human Ovarian Cancer Cells to Cisplatin by Modulating Platinum-DNA Damage Responses

Muenyi, C. S., Pinhas, A. R., Fan, T. W. ‐., Brock, G. N., Helm, C. W., & States, J. C. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs085 · Cited by 26

Glioma in Schizophrenia: Is the Risk Higher or Lower?

Gao, X., Mi, Y., Guo, N., Xu, H., Jiang, P., Zhang, R., Xu, L., & Gou, X. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00289 · Cited by 26

Acrolein Is Involved in the Synergistic Potential of Cigarette Smoking– and Betel Quid Chewing–Related Human Oral Cancer

Tsou, H., Hu, C.-H., Liu, J.-H., Liu, C., Lee, C., Liu, T.-Y., & Wang, H. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1033 · Cited by 26

Label-Free Electrochemical Detection of the p53 Core Domain Protein on Its Antibody Immobilized Electrode

Yeo, J., Park, J., Bae, W. J., Lee, L. Y. S., Kim, B. H., Cho, Y., & Park, S. (2009) · Analytical Chemistry · doi:10.1021/ac900301h · Cited by 26

Nucleotide excision repair phenotype of human acute myeloid leukemia cell lines at various stages of differentiation

Hsu, P.-H., Hanawalt, P. C., & Nouspikel, T. (2006) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.06.008 · Cited by 27

The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures

Guay, D. R. P., Evoy, A.-A., Paquet, É. R., Garand, C., Bachvarova, M., Bachvarov, D. R., & Lebel, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.04.011 · Cited by 26

TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas

Lima-Ramos, V., Pacheco‐Figueiredo, L., Costa, S., Pardal, F., Silva, A., de Amorim, J. A., Lopes, J. M., & Reis, R. M. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.08.019 · Cited by 26

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose‐intensive chemotherapy including rituximab

Forero‐Castro, M., Robledo, C., Lumbreras, E., Benito, R., Hernández-Sánchez, J. M., Hernández‐Sánchez, M., Garcı́a, J. L., Corchete, L. A., Tormo, M., Barba, P., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13849 · Cited by 25

Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways

Stępiński, D. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-016-1443-6 · Cited by 27

Association of EGF, IGFBP-3 and TP53 Gene Polymorphisms with Major Depressive Disorder in Slovak Population

Mahmood, S., Evinová, A., Škereňová, M., Ondrejka, I., & Lehotský, J. (2016) · Central European Journal of Public Health · doi:10.21101/cejph.a4301 · Cited by 25

Sophisticated Framework between Cell Cycle Arrest and Apoptosis Induction Based on p53 Dynamics

Hamada, H., Tashima, Y., kisaka, Y., Iwamoto, K., Hanai, T., Eguchi, Y., & Okamoto, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004795 · Cited by 25

Focus on the p53 gene and cancer: Advances inTP53 mutation research

Soussi, T. (2003) · Human Mutation · doi:10.1002/humu.10191 · Cited by 25

The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers

Olivier, M., Hainaut, P. L., & Petitjean, A. (2007) · IATREIA

IARC TP53 Database

Olivier, M., & Hainaut, P. L. (2008) · Springer eBooks · doi:10.1007/978-3-540-47648-1_2934 · Cited by 1

Untitled work

(1999) · doi:10.1002/(sici)1098-1004(1999)14:1

TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data: Human Mutation

Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730

Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects

Hainaut, P. L., Soussi, T., Shomer, B., Hollstein, M. C., Greenblatt, M. S., Hovig, E. J., Harris, C. C., & Montesano, R. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.1.151 · Cited by 299